subscribeSubscribe
price-trendAsk Us
Vifor`s hyperkalaemia drug Veltassa shows benefit in heart failure patients

Vifor`s hyperkalaemia drug Veltassa shows benefit in heart failure patients
BUSINESSWIRE
21 Dec 2021
Share Share
Vifor reports positive outcome of the phase-IIIb DIAMOND trial of Veltassa

Vifor reports positive outcome of the phase-IIIb DIAMOND trial of Veltassa
BUSINESSWIRE
20 Dec 2021
Share Share
Vifor`s Ferinject® granted new recommendations in ESC heart failure guidelines

Vifor`s Ferinject® granted new recommendations in ESC heart failure guidelines
BUSINESSWIRE
31 Aug 2021
Share Share
NICE reverses previous decision to recommend Vifor Pharma`s Veltassa for NHS

NICE reverses previous decision to recommend Vifor Pharma`s Veltassa for NHS
PHARMAFILE
16 Dec 2019
Share Share
Vifor Pharma’s Phase-II AMBER Study Meets Primary Endpoint

Vifor Pharma’s Phase-II AMBER Study Meets Primary Endpoint
BUSINESSWIRE
13 May 2019
Share Share
Vifor Pharma’s Phase-II AMBER Study Meets Primary Endpoint

Vifor Pharma’s Phase-II AMBER Study Meets Primary Endpoint
BUSINESSWIRE
10 May 2019
Share Share
NICE turns down hyperkalaemia therapies

NICE turns down hyperkalaemia therapies
Selina McKee PHARMA TIMES
30 Oct 2018
Share Share